AVITA Medical, Inc. (NASDAQ:RCEL) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET

Company Participants

Jessica Ekeberg - Director, Investor Relations
Jim Corbett - Chief Executive Officer
David O'Toole - Chief Financial Officer

Conference Call Participants

Ryan Zimmerman - BTIG
Joshua Jennings - TD Cowen
Aaron Wukmir - Lake Street Capital Market
Ross Osborne - Cantor Fitzgerald
Lyanne Harrison - Bank of America

Operator

Good day and thank you for standing by. Welcome to the AVITA Medical Second Quarter Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Jessica Ekeberg, Director of Investor Relations.

Jessica Ekeberg

Thank you, operator. Welcome to AVITA Medical’s second quarter 2024 earnings call. Joining me on today's call are Jim Corbett, Chief Executive Officer, and David O'Toole, Chief Financial Officer. Today's earnings release and presentation are available on our website, www.avitamedical.com. under the investor relations section.

Before we begin, I'd like to remind you that this call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are neither promises nor guarantees and involve known and unknown risks and uncertainties. That could cause actual results to differ materially from any expectations expressed or implied by the forward-looking statements.

Please review our most recent filings with the SEC for comprehensive descriptions of the risk factors. Any forward-looking statements provided during this call are based on management's expectations as of today.

I will now turn the call over to Jim for his comments.

Jim Corbett

Thank you, Jessica. Good afternoon, and thank you for joining us today. I will begin today's call by discussing our financial and business results for the second quarter, followed by our priorities and outlook for the remainder of 2024. Following this update, I will turn the call over to David, who will provide commentary on our financial performance for the quarter before opening the call to Q&A.

During the quarter, we focused on addressing the challenges we faced in the first quarter by implementing enhanced coverage strategy and other strategic initiatives focused on execution. Our commitment to these efforts and sustaining growth are reflected in our second quarter commercial revenue of $15.1 million, which was at the higher end of our previously provided guidance range of $14.3 million to $15.3 million.